The iconic rise of Viagra has consistently remained a benchmark of pharmaceutical success, yet its legacy within the broader industry now triggers questions about future gains. Copycat versions are diminishing market share, leading to anxieties that investing in companies significantly dependent to Viagra's previous position could be a problematic